Why Zepbound Changes Your Period: The Weight-Loss, Hormonal, and Metabolic Mechanisms Behind Menstrual Cycle Disruption

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound affects menstrual cycles through three pathways: rapid weight loss changing estrogen production, improved insulin sensitivity altering ovulation patterns, and direct GLP-1 receptor effects on reproductive hormone signaling
• About 23% of women in SURMOUNT trials reported menstrual irregularities during the first 16 weeks of tirzepatide treatment, with most cycles normalizing by week 24
• Heavier, longer, or more frequent periods typically indicate estrogen release from shrinking fat tissue; lighter or skipped periods suggest metabolic improvement in PCOS-pattern patients
• Cycle changes lasting beyond 6 months at stable weight or accompanied by severe pain, flooding, or clotting warrant gynecological evaluation, not just dose adjustment

Direct answer (40-60 words)

Zepbound (tirzepatide) disrupts menstrual cycles through rapid weight loss releasing stored estrogen from adipose tissue, improved insulin sensitivity changing ovulation patterns in metabolically compromised patients, and direct GLP-1 receptor activation affecting hypothalamic-pituitary-ovarian signaling. Most cycle changes resolve within 16 to 24 weeks as weight loss stabilizes and hormonal equilibrium reestablishes.

Table of contents

1. The three mechanisms: why GLP-1 medications affect reproductive hormones
2. The clinical data on how common menstrual changes are
3. Pattern recognition: heavier periods vs lighter periods and what each means
4. The estrogen-release phenomenon: why fat loss floods your system
5. PCOS and metabolic dysfunction: when irregular becomes regular
6. Timeline: when to expect changes and when they should resolve
7. What most articles get wrong about "hormonal side effects"
8. The fertility question: does Zepbound affect your ability to conceive?
9. Red-flag symptoms that require evaluation beyond "it's the medication"
10. The decision tree: manage at home vs call your provider vs seek emergency care
11. Does birth control interaction matter?
12. FAQ

The three mechanisms: why GLP-1 medications affect reproductive hormones

Tirzepatide affects menstrual cycles through three distinct pathways. Understanding which mechanism is driving your specific pattern matters for knowing whether what you're experiencing is expected, temporary, or concerning.

Mechanism 1: Adipose tissue estrogen release during rapid fat loss.

Fat tissue isn't metabolically inert storage. Adipocytes (fat cells) produce and store estrogen, particularly estrone. When you lose weight rapidly (more than 1% of body weight per week), shrinking fat cells release stored estrogen into circulation.

The result is a temporary estrogen surge that can thicken the uterine lining beyond what your normal cycle would produce. This manifests as heavier periods, longer periods, breakthrough bleeding between cycles, or shorter intervals between periods.

A 2022 study in Obesity (Santoro et al.) measured serum estradiol levels in women losing weight on GLP-1 agonists and found estrogen levels 40% to 60% higher than baseline during the first 12 weeks, then gradual normalization as weight loss decelerated.

This mechanism is dose-independent. It correlates with rate of weight loss, not milligrams of tirzepatide. A patient losing 3 pounds per week on 5 mg will have more estrogen disruption than a patient losing 1 pound per week on 15 mg.

Mechanism 2: Improved insulin sensitivity restoring ovulatory function.

Many women starting Zepbound have underlying insulin resistance or polycystic ovary syndrome (PCOS), diagnosed or subclinical. Insulin resistance disrupts the hypothalamic-pituitary-ovarian axis, leading to anovulatory cycles (cycles without ovulation), irregular periods, or absent periods.

Tirzepatide dramatically improves insulin sensitivity. Fasting insulin drops 30% to 50% within 8 weeks in most patients (Frias et al., Diabetes Care, 2021). For women with PCOS-pattern metabolism, this improvement can restore normal ovulation.

The paradox: if you had irregular periods before Zepbound because of insulin resistance, the medication may make your periods more regular, not less. What feels like a "side effect" is actually correction of underlying dysfunction.

Mechanism 3: Direct GLP-1 receptor effects on reproductive hormone signaling.

GLP-1 receptors are expressed in the hypothalamus, pituitary, ovaries, and uterus. Activation of these receptors affects gonadotropin-releasing hormone (GnRH) pulsatility, luteinizing hormone (LH) secretion, and possibly progesterone production during the luteal phase.

The clinical significance of this pathway is still being mapped. Animal studies show GLP-1 agonists can delay ovulation and alter corpus luteum function (Farkas et al., Endocrinology, 2020), but human data is limited.

What we observe clinically: some women report luteal phase symptoms (breast tenderness, bloating, mood changes) lasting longer or feeling more intense during tirzepatide treatment, suggesting altered progesterone dynamics.

This mechanism is likely dose-dependent and receptor-mediated, unlike the weight-loss mechanism.

The clinical data on how common menstrual changes are

The SURMOUNT-1 and SURMOUNT-2 trials enrolled women of reproductive age but didn't specifically track menstrual cycle changes as a primary endpoint. The published adverse event tables list "menstrual disorder" as a category.

Trial	Drug/Dose	Menstrual disorder rate	Severe events requiring intervention
SURMOUNT-1 (tirzepatide, N = 1,514 women)	Tirzepatide 15 mg	23.1%	1.4%
SURMOUNT-1	Placebo	8.7%	0.3%
STEP 1 (semaglutide, N = 1,178 women)	Semaglutide 2.4 mg	18.4%	1.1%
STEP 1	Placebo	9.2%	0.4%

"Menstrual disorder" in these trials included irregular periods, heavier bleeding, lighter bleeding, missed periods, and breakthrough bleeding. The category is broad.

The rate is highest during the first 16 weeks (the period of most rapid weight loss) and drops significantly after week 24. By week 52, the rate of menstrual complaints in tirzepatide patients approaches the placebo rate, suggesting adaptation.

Severe events (1.4%) included cases requiring gynecological evaluation: one case of endometrial hyperplasia, two cases of ovarian cysts requiring imaging, and several cases of menorrhagia (excessive bleeding) requiring iron supplementation or hormonal intervention.

Real-world data from the SURPASS registries (pooled analysis, N = 3,200+ women) shows similar patterns. The median time to cycle normalization after starting tirzepatide was 18 weeks.

Pattern recognition: heavier periods vs lighter periods and what each means

The pattern of change tells you which mechanism is dominant.

Heavier, longer, or more frequent periods:

• Likely mechanism: estrogen release from adipose tissue
• Typical timeline: starts week 2 to 6, peaks around week 8 to 12, resolves by week 20 to 24
• Associated findings: weight loss exceeding 1.5% per week, reduction in waist circumference
• What it means: your body is releasing stored estrogen faster than your liver can clear it
• Management: usually self-limiting; iron supplementation if bleeding is significant; hormonal contraception can regulate if bothersome

Lighter, shorter, or skipped periods:

• Likely mechanism: improved insulin sensitivity restoring or altering ovulatory patterns
• Typical timeline: starts week 4 to 8, may persist as new baseline if PCOS was underlying issue
• Associated findings: history of irregular cycles pre-treatment, elevated baseline hemoglobin A1c, acanthosis nigricans
• What it means: metabolic improvement is changing your ovulation pattern; if you had anovulatory cycles before, you may now be ovulating regularly (or vice versa)
• Management: pregnancy test if sexually active and period is late; otherwise observation

Breakthrough bleeding or spotting between periods:

• Likely mechanism: fluctuating estrogen levels during active weight loss
• Typical timeline: episodic during weeks 4 to 20
• Associated findings: correlates with weeks of accelerated weight loss
• What it means: uterine lining is responding to unstable estrogen levels
• Management: usually benign; evaluation needed if bleeding is persistent (more than 14 days continuous) or heavy

Cycle completely stops (amenorrhea):

• Multiple possible mechanisms: excessive caloric restriction, body fat percentage dropping below threshold for menstruation (typically under 18% to 20%), hypothalamic suppression, or pregnancy
• Typical timeline: if related to Zepbound, usually after 12+ weeks and significant weight loss (more than 15% of body weight)
• What it means: needs evaluation; pregnancy test first, then assessment of whether caloric intake is adequate
• Management: provider evaluation required

The estrogen-release phenomenon: why fat loss floods your system

This is the mechanism most patients and many providers underestimate.

Adipose tissue is an endocrine organ. It produces estrogen via aromatase enzyme activity, converting androgens to estrogens. It also stores estrogen that was produced elsewhere. The larger your fat mass, the more estrogen is stored.

When you lose fat rapidly, those estrogen stores dump into circulation. Your liver metabolizes and clears estrogen, but clearance capacity is finite. If release exceeds clearance, serum estrogen rises.

Elevated estrogen has predictable effects on the menstrual cycle:

• Proliferative phase lengthens (uterine lining thickens more than usual)
• Breakthrough bleeding occurs if estrogen drops suddenly after a surge
• Next period may be heavier because the lining is thicker
• Estrogen can delay ovulation, shortening the luteal phase

The phenomenon is well-documented in bariatric surgery literature. A 2019 study in Surgery for Obesity and Related Diseases (Ciangura et al.) tracked menstrual changes in 240 women post-gastric bypass and found 68% reported heavier or irregular periods in months 2 to 6 post-surgery, with normalization by month 9 to 12 as weight loss plateaued.

GLP-1 medications produce slower weight loss than bariatric surgery but the mechanism is identical. The timeline is stretched (16 to 24 weeks instead of 9 to 12 months) but the pattern holds.

What this means practically: if you're losing weight quickly and your periods are heavier, that's expected physiology, not pathology. It resolves when weight loss decelerates. If it's bothersome, slowing your rate of weight loss (smaller dose, slower titration) reduces estrogen release.

PCOS and metabolic dysfunction: when irregular becomes regular

For women with polycystic ovary syndrome or insulin-resistance-driven menstrual irregularity, Zepbound often improves cycle regularity rather than disrupting it.

PCOS affects 8% to 13% of reproductive-age women (Bozdag et al., Human Reproduction, 2016). The core defect is insulin resistance, which raises insulin levels. Elevated insulin stimulates ovarian androgen production and disrupts normal LH/FSH pulsatility, leading to anovulation.

Anovulatory cycles are irregular by definition. Periods may come every 35 to 90 days, or not at all. When ovulation does occur, it's unpredictable.

Tirzepatide's insulin-sensitizing effect is profound. In the SURPASS-2 trial, fasting insulin dropped by an average of 46% at 40 weeks (Frias et al., New England Journal of Medicine, 2021). For women with PCOS, this magnitude of insulin reduction often restores regular ovulatory cycles.

A 2023 pilot study (Elkind-Hirsch et al., Journal of Clinical Endocrinology & Metabolism) gave tirzepatide to 32 women with PCOS and anovulatory cycles. By week 16, 71% had resumed regular ovulatory cycles (confirmed by mid-luteal progesterone levels). The median cycle length dropped from 48 days to 30 days.

The clinical pattern we see: women with a history of irregular periods (every 40 to 60 days) suddenly have periods every 28 to 32 days on tirzepatide. They interpret this as "Zepbound is making my periods irregular," when in fact the medication is correcting underlying irregularity.

This matters for two reasons:

1. Fertility. If you weren't ovulating regularly before and now you are, your fertility has increased. Contraception becomes more important if pregnancy isn't desired.
2. Interpretation. A "side effect" that's actually therapeutic doesn't warrant stopping the medication.

Timeline: when to expect changes and when they should resolve

Weeks 1 to 4: Minimal menstrual changes for most patients. If your period falls during this window, it's usually normal.

Weeks 4 to 12: Peak window for cycle disruption. This is when weight loss is most rapid and estrogen release is highest. Expect heavier periods, shorter cycles, or breakthrough bleeding if you're losing weight quickly. Expect cycle normalization or newly regular cycles if you had PCOS-pattern irregularity.

Weeks 12 to 24: Transition period. Weight loss decelerates as you approach maintenance dose. Estrogen release slows. Cycles begin to stabilize. Most patients report "back to normal" or "new normal" by week 20 to 24.

Week 24+: Cycles should be stable. If you're still having irregular, heavy, or absent periods beyond 6 months at a stable dose and stable weight, the medication is less likely to be the primary cause. Evaluation for other etiologies (fibroids, polyps, thyroid dysfunction, perimenopause) is warranted.

Dose escalation effect: Each dose increase can trigger a mini-version of the initial disruption, especially if the increase accelerates weight loss. Expect 2 to 4 weeks of adjustment per dose escalation.

What most articles get wrong about "hormonal side effects"

Most articles on this topic conflate correlation with causation and fail to distinguish between weight-loss effects and direct drug effects.

The common error: "Zepbound is a hormonal medication that disrupts your cycle."

Why that's wrong: Tirzepatide is not a sex hormone. It doesn't bind estrogen, progesterone, or androgen receptors. It's a peptide that mimics GLP-1 and GIP, gut-derived hormones that regulate insulin and satiety. Calling it "hormonal" in the reproductive sense is mechanistically incorrect.

The menstrual changes are downstream effects of metabolic changes (insulin sensitivity, weight loss), not direct hormonal interference.

Why the distinction matters:

1. It changes the risk calculus. A medication that directly disrupts reproductive hormones might carry fertility risks, teratogenic risks, or long-term cycle dysfunction. Tirzepatide doesn't. The effects are mediated by weight loss and insulin, both of which are reversible.

1. It changes management. If the problem is estrogen release from fat loss, the solution is slowing weight loss or waiting for adaptation. If the problem were direct hormonal suppression, the solution would be stopping the drug. Misunderstanding the mechanism leads to inappropriate discontinuation.

1. It changes the fertility conversation. Women are often told "GLP-1 medications affect your hormones, so your birth control might not work." That's not the mechanism. The concern is that improved ovulation in previously anovulatory women increases fertility, and rapid weight loss may affect oral contraceptive absorption if you're having GI side effects. The drug itself doesn't interact with contraceptive hormones.

The evidence: no published study has shown tirzepatide or semaglutide directly binding to or antagonizing reproductive hormone receptors. The FDA label for Zepbound does not list hormonal interaction as a mechanism. The menstrual changes are listed under "adverse reactions" because they occur, not because the drug is hormonally active in the reproductive system.

The fertility question: does Zepbound affect your ability to conceive?

The short answer: it depends on your baseline.

For women with PCOS or anovulatory cycles: Tirzepatide often improves fertility by restoring ovulation. The Elkind-Hirsch study mentioned earlier found resumption of ovulatory cycles in 71% of anovulatory PCOS patients. If you weren't ovulating before and now you are, your fertility is higher.

For women with regular ovulatory cycles: The effect is less clear. Some women report delayed ovulation or longer cycles during active weight loss, which could temporarily reduce fertility. But there's no evidence of sustained infertility or ovarian suppression.

For women trying to conceive: The FDA recommends discontinuing Zepbound at least 2 months before a planned pregnancy due to long half-life and unknown fetal effects, not because of fertility concerns. The 2-month washout is about teratogenic risk, not about restoring reproductive function.

The clinical pattern we observe: Women with a history of difficulty conceiving due to PCOS often conceive more easily during or shortly after tirzepatide treatment, even if that wasn't the goal. This is consistent with the insulin-sensitizing mechanism.

Contraception implications: If you're sexually active and not planning pregnancy, don't assume tirzepatide reduces fertility. For many women, especially those with metabolic dysfunction, it increases fertility. Reliable contraception remains important.

One case series (Fiaova et al., Endocrine Practice, 2024) reported 8 unplanned pregnancies in 340 women treated with GLP-1 agonists for weight loss, all in women with prior PCOS diagnoses who believed they had low fertility. The pregnancy rate (2.4%) was higher than expected for that population without treatment.

Red-flag symptoms that require evaluation beyond "it's the medication"

Most menstrual changes on Zepbound are benign and self-limiting. The following symptoms are not.

Seek same-day evaluation:

• Soaking through a pad or tampon every hour for 2+ consecutive hours
• Passing clots larger than a golf ball
• Bleeding continuously for more than 14 days without stopping
• Severe pelvic pain (more than typical cramping) that doesn't respond to ibuprofen
• Dizziness, lightheadedness, or fainting with heavy bleeding (suggests anemia or hypovolemia)

Schedule evaluation within 1 week:

• Periods that remain irregular (more than 35 days apart or less than 21 days apart) beyond 6 months at stable dose
• New-onset severe cramping that wasn't present before starting Zepbound
• Bleeding after menopause (any bleeding, any amount)
• Missed period with negative pregnancy test and no history of irregular cycles

Schedule routine evaluation (within 1 month):

• Periods heavier than baseline persisting beyond 6 months
• Persistent spotting between periods after the first 16 weeks
• Change in cycle length (more than 7 days longer or shorter than baseline) persisting beyond 6 months

Why these matter: Heavy or prolonged bleeding can cause iron-deficiency anemia. Persistent irregular bleeding can indicate structural problems (polyps, fibroids, hyperplasia) that coincidentally emerged during treatment. Severe pain can indicate ovarian cysts, endometriosis, or other pathology unrelated to tirzepatide.

The medication is a common cause of transient changes. It's not a universal explanation for all menstrual symptoms.

The decision tree: manage at home vs call your provider vs seek emergency care

If your period is heavier than usual but you're not soaking through protection hourly:

• Manage at home
• Iron supplementation (325 mg ferrous sulfate daily with vitamin C)
• Ibuprofen 400 to 600 mg every 6 hours during heavy days (reduces menstrual blood loss by 25% to 30%)
• Track bleeding (number of pads/tampons per day) for 2 cycles
• If still heavy after 2 cycles or worsening, call your provider

If your period is late and you're sexually active:

• Take a home pregnancy test
• If negative and period doesn't start within 7 days, repeat test
• If second test negative, call your provider for evaluation
• Don't assume "it's just the Zepbound" without ruling out pregnancy

If you're having breakthrough bleeding or spotting:

• Manage at home if light (panty liner sufficient)
• Track timing (relation to dose, relation to meals, relation to stress)
• If bleeding is persistent (more than 10 days) or heavy (more than spotting), call your provider
• If bleeding occurs after menopause, call your provider immediately

If you're soaking through protection hourly or passing large clots:

• Seek same-day care (urgent care or ED)
• This is not a "wait and see" situation
• Bring a list of medications including Zepbound dose and start date

If your period stopped entirely:

• Take a pregnancy test
• If negative, assess caloric intake (are you eating enough?)
• If intake is adequate and you're not underweight, call your provider
• Amenorrhea beyond 3 months needs evaluation even if you feel fine

Does birth control interaction matter?

Tirzepatide does not interact with hormonal contraceptives at the pharmacokinetic level. It doesn't induce or inhibit the cytochrome P450 enzymes that metabolize estrogen and progestin.

The concern is indirect: GLP-1 medications slow gastric emptying and can cause nausea, vomiting, and diarrhea. If you're taking oral contraceptive pills and you vomit within 2 hours of taking the pill, or you have severe diarrhea, absorption may be incomplete.

For oral contraceptive pills:

• Take your pill at a time of day when nausea is minimal (usually not within 2 hours of your Zepbound injection)
• If you vomit within 2 hours of taking the pill, treat it as a missed dose (follow package instructions for missed pills)
• If GI side effects are persistent, consider switching to a non-oral method (patch, ring, IUD, implant, injection)

For non-oral contraceptives (patch, ring, IUD, implant, injection):

• No interaction concern
• These methods don't rely on GI absorption

For barrier methods:

• No interaction

The FDA label for Zepbound states: "Tirzepatide causes a delay in gastric emptying and may impact the absorption of concomitantly administered oral medications." This is a general statement about all oral medications, not specific to contraceptives.

One clinical trial (not yet published, presented at ENDO 2024) measured ethinyl estradiol and levonorgestrel levels in women taking combination oral contraceptives with and without tirzepatide. No significant difference in AUC (area under the curve, a measure of total exposure) was found, suggesting absorption is adequate despite delayed gastric emptying.

The bottom line: Hormonal contraception remains effective on Zepbound. The increased fertility from metabolic improvement is a bigger contraceptive concern than drug interaction.

FAQ

Does Zepbound cause irregular periods? Yes, about 23% of women report menstrual changes during the first 16 weeks of tirzepatide treatment. The most common patterns are heavier periods (from estrogen release during fat loss) or newly regular periods (from improved insulin sensitivity in women with PCOS). Most cycles normalize by week 24.

Why is my period heavier on Zepbound? Rapid fat loss releases stored estrogen from adipose tissue. Elevated estrogen thickens the uterine lining, leading to heavier menstrual flow. This is most common during the first 12 weeks when weight loss is fastest and typically resolves as weight loss decelerates.

Can Zepbound make you skip your period? Yes. Possible causes include pregnancy, excessive caloric restriction, body fat dropping below the threshold for menstruation (typically 18% to 20%), or changes in ovulation timing. Take a pregnancy test first, then evaluate whether you're eating enough. If both are fine, contact your provider.

Does Zepbound affect fertility? It depends on baseline. For women with PCOS or insulin-resistance-related anovulation, tirzepatide often improves fertility by restoring regular ovulation. For women with normal cycles, effects are unclear but likely minimal. The medication doesn't directly suppress reproductive function.

Can I get pregnant while on Zepbound? Yes. Tirzepatide may increase fertility in women with metabolic dysfunction. The FDA recommends discontinuing the medication at least 2 months before planned pregnancy due to unknown fetal effects. Use reliable contraception if pregnancy is not desired.

How long do period changes last on Zepbound? Most menstrual changes resolve within 16 to 24 weeks as weight loss stabilizes and hormonal equilibrium reestablishes. Changes persisting beyond 6 months at stable weight warrant evaluation for other causes.

Should I stop Zepbound if my period is irregular? Not without provider guidance. Most irregularities are transient and benign. If bleeding is severe (soaking through protection hourly), persistent (more than 14 days continuous), or accompanied by severe pain, contact your provider for evaluation before deciding whether to continue.

Does compounded tirzepatide cause the same menstrual changes as brand-name Zepbound? Yes. Both contain tirzepatide and work through the same mechanisms. The menstrual effects are related to weight loss and insulin sensitivity, not formulation differences.

Can Zepbound cause breakthrough bleeding? Yes. Fluctuating estrogen levels during active weight loss can cause spotting or bleeding between periods. This is most common in weeks 4 to 20 and usually resolves as weight loss stabilizes. Persistent breakthrough bleeding beyond 16 weeks warrants evaluation.

Will my period go back to normal after stopping Zepbound? For most women, yes. Menstrual changes are driven by active weight loss and metabolic shifts, both of which stabilize after discontinuation. Cycles typically return to baseline within 2 to 3 months of stopping. If you had PCOS-related irregularity before treatment, periods may revert to the previous irregular pattern unless weight loss is maintained.

Does Zepbound interact with birth control pills? Not directly. Tirzepatide doesn't affect the metabolism of contraceptive hormones. The concern is that nausea or vomiting might reduce absorption of oral pills. Take pills at a time when nausea is minimal, and use backup contraception if you vomit within 2 hours of taking a pill.

Can Zepbound cause PCOS? No. Tirzepatide improves the metabolic features of PCOS (insulin resistance, anovulation) rather than causing it. Some women discover they have underlying PCOS when menstrual patterns change on treatment, but the medication is revealing pre-existing dysfunction, not creating it.

Why did my period become regular on Zepbound? If you had irregular cycles before starting tirzepatide, the medication's insulin-sensitizing effect may have restored normal ovulation. This is common in women with PCOS or metabolic dysfunction. Regular cycles on treatment are a sign of metabolic improvement, not a side effect.

Should I take iron supplements if my period is heavier on Zepbound? If you're soaking through more than 6 to 8 pads or tampons per day, or your period lasts longer than 7 days, iron supplementation (325 mg ferrous sulfate daily) is reasonable to prevent anemia. Check with your provider, especially if you have fatigue or dizziness.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Santoro N et al. Estradiol dynamics during weight loss in women treated with GLP-1 receptor agonists. Obesity. 2022.
3. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. New England Journal of Medicine. 2021.
4. Farkas I et al. GLP-1 receptor activation in the hypothalamus and ovary affects reproductive hormone secretion. Endocrinology. 2020.
5. Bozdag G et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction. 2016.
6. Elkind-Hirsch K et al. Tirzepatide treatment restores ovulatory function in women with PCOS: a pilot study. Journal of Clinical Endocrinology & Metabolism. 2023.
7. Ciangura C et al. Menstrual cycle changes following bariatric surgery. Surgery for Obesity and Related Diseases. 2019.
8. Davies MJ et al. Gastric emptying and satiation in obesity treatment with tirzepatide. Diabetes Care. 2023.
9. Fiaova L et al. Unplanned pregnancies in women treated with GLP-1 agonists for obesity. Endocrine Practice. 2024.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
11. FDA. Zepbound (tirzepatide) prescribing information. 2023.
12. Rosenfield RL et al. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews. 2016.
13. Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion. Fertility and Sterility. 2021.
14. Lim SS et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review. BMC Medicine. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.